# A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM

> **NCT03723655** · PHASE2,PHASE3 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 314 (actual)

## Conditions studied

- Hypertrophic Cardiomyopathy
- Obstructive Hypertrophic Cardiomyopathy
- Non-obstructive Hypertrophic Cardiomyopathy

## Interventions

- **DRUG:** mavacamten

## Key facts

- **NCT ID:** NCT03723655
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-27
- **Primary completion:** 2026-01-16
- **Final completion:** 2026-01-16
- **Target enrollment:** 314 (ACTUAL)
- **Last updated:** 2026-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03723655

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03723655, "A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03723655. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*